Renal congestion is caused by elevated central venous pressure (CVP), and decreases glomerular filtration in patients with congestive heart failure. Since real-time contrast-enhanced ultrasonography (CEUS) using microbubble-based contrast agents can visualize the perfused microvascular bed, we sought to evaluate the impairment of renal perfusion during acute renal congestion with CEUS. In Wister rats, CEUS of kidney was performed with the direct monitoring of CVP and intra-renal pressure (IRP). When CVP was elevated to 10 and 15 mmHg after the bolus injection of normal saline via the femoral vein, peak intensity (PI, dB) and time to PI (TTP) in the renal cortex and medulla were compared with control rats. There was a strong correlation between IRP and CVP (r = 0.95, p < 0.0001). In the congestion model, more time was required for enhancement of the parenchyma, especially in the medulla compared to control; TTP of the medulla and cortex at 15 mmHg CVP (CVP15) was significantly prolonged compared with controls (medulla, 4351 ± 98 vs. 1415 ± 267 ms, p = 0.003; cortex, 3219 ± 106 vs. 1335 ± 264 ms, p = 0.005). In addition, medullary PI at CVP15 decreased, but not significantly, compared to those of controls and at 10 mmHg CVP (20.1 ± 0.9, 22.8 ± 1.6, 21.6 ± 0.2 dB). In contrast, cortical PIs at CVP15 were significantly lower than that of control (24.6 ± 1.0 vs. 31.4 ± 1.0 dB, p = 0.007). CEUS revealed that impaired renal parenchymal flow in an acute congestion model is accompanied with increased renal interstitial pressure.
including changes in renal perfusion early in the course of renal allograft nephropathy 10,11 and renal artery stenosis. 12 Furthermore, it has been experimentally applied in induced acute kidney injury models. 13, 14 We recently reported that successful visualization of renal perfusion disturbances using CEUS was possible in rat models of acute renal congestion. 15 Based on these results, we hypothesized that human renal congestion could also be evaluated using CEUS.Therefore, in this study, we quantified renal congestion in CHF patients on renal perfusion imaging using CEUS. Methods Study DesignIn total, 11 patients (7 men, 4 women; mean age, 81±8 years) who were hospitalized with a diagnosis of CHF using the Framingham Congestive Heart Failure Diagnostic criteria were enrolled. 16 Obvious symptoms of right-sided HF were recognized in all patients, included leg edema, shortness of breath, pleural effusion, pulmonary hypertension, moderate or severe tricuspid regurgitation (TR), and a decline of inspiratory collapse in the inferior vena cava (IVC). As part of the inclusion criteria for this study, all patients were Background: Renal congestion is a critical pathophysiological component of congestive heart failure (CHF). Methods and Results:To quantify renal congestion, contrast-enhanced ultrasonography (CEUS) was performed at baseline and after treatment in 11 CHF patients and 9 normal subjects. Based on the time-contrast intensity curve, time to peak intensity (TTP), which reflects the perfusion rate of renal parenchyma, and relative contrast intensity (RCI), an index reflecting renal blood volume, were measured. In CHF patients, TTP at baseline was significantly prolonged compared with that in controls (cortex, 10.8±3.5 vs. 4.6±1.2 s, P<0.0001; medulla, 10.6±3.0 vs. 5.1±1.6 s, P<0.0001), and RCI was lower than that in controls (cortex, −16.5±5.2 vs. −8.8±1.5 dB, P<0.0001; medulla, −22.8±5.2 vs. −14.8±2.4 dB, P<0.0001). After CHF treatment, RCI was significantly increased (cortex, −16.5±5.2 to −11.8±4.5 dB, P=0.035; medulla, −22.8±5.2 to −18.7±3.7 dB, P=0.045). TTP in the cortex decreased after treatment (10.8±3.5 to 7.6±3.1 s, P=0.032), but it was unchanged in the medulla (10.6±3.0 to 8.3±3.2 s, P=0.098). Conclusions:Renal congestion can be observed using CEUS in CHF patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.